4/A: Citius Oncology Director Carol Webb Granted 300,000 RSUs

Citius Oncology Director Carol Webb received a grant of 300,000 restricted stock units, vesting on the third anniversary of the grant date.

Summary

• Carol Webb, a Director of Citius Oncology, Inc. (CTOR), was granted 300,000 restricted stock units (RSUs).
• The grant date for these RSUs was September 19, 2025.
• The shares underlying these RSUs will vest in full on the third anniversary of the grant date, which is September 19, 2028.
• Vesting is contingent upon Ms. Webb's continuous service to Citius Oncology, Inc. or a related entity.
• The transaction price for these RSUs was $0, which is standard for such grants.
• Following this transaction, Ms. Webb beneficially owns 300,000 shares directly.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a director is a positive sign of alignment between management and shareholder interests, promoting long-term commitment. It's a standard compensation practice, so not exceptionally positive, but certainly not negative.

Positives

• The grant of 300,000 restricted stock units to a Director aligns her interests with long-term shareholder value.
• The vesting schedule encourages continuous service and commitment from a key board member.

Negatives

• No immediate cash value for the recipient until vesting.
• Potential for minor dilution for existing shareholders upon vesting, though this is a common form of executive compensation.

Risks

• The vesting of the restricted stock units is subject to the Reporting Person's Continuous Service, meaning if service terminates before the vesting date, the shares may be forfeited.

Future Outlook

The vesting schedule for the restricted stock units on September 19, 2028, indicates a long-term incentive for the director to remain with the company and contribute to its future success.

Management Comments

• Represents restricted stock units granted on September 19, 2025. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date.

Industry Context

Equity grants like restricted stock units are a common compensation tool in the biotechnology and pharmaceutical industry, particularly for directors and executives, to align their interests with long-term company performance and shareholder value. This practice is standard across publicly traded companies, especially those in development-stage sectors like oncology, where long-term commitment is crucial.

Comparison to Industry Standards

• The grant of restricted stock units to a director is a standard practice for executive and board compensation in publicly traded companies, particularly in the biotech sector.
• A three-year cliff vesting schedule is common for such grants, aiming to retain key personnel and incentivize long-term performance, comparable to practices at companies like Moderna or BioNTech for their board members.
• The $0 transaction price is typical for RSU grants, as they represent a right to receive shares in the future, not a purchase.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for minor dilution upon vesting of the 300,000 shares, but also benefits from increased alignment of director interests with long-term company performance.
• Directors: Carol Webb receives a significant long-term incentive, contingent on her continued service.

Next Steps

• The shares will vest on September 19, 2028, subject to continuous service.

Key Dates

Recommendation

This filing details a routine equity grant to a director, which is a standard compensation practice aimed at aligning interests. It does not contain information that would fundamentally alter the investment thesis for Citius Oncology, Inc. Therefore, a "hold" recommendation is appropriate, as this event alone is unlikely to drive significant price movement or change the company's underlying value proposition. Investors should continue to monitor the company's operational and financial performance.

Keywords

Citius Oncology, CTOR, Carol Webb, Restricted Stock Units, RSU, Director Compensation, Insider Ownership, SEC Form 4, Equity Grant, Vesting